Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
about
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancerCisplatin versus carboplatin in association with third-generation drugs for advanced non-small cell lung cancerOptimizing the management of advanced non-small-cell lung cancer: a personal viewNew targeted treatments for non-small-cell lung cancer - role of nivolumabPersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for CeritinibMolecular landscape of pancreatic cancer: implications for current clinical trialsA comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancerCan microRNAs improve the management of lung cancer patients? A clinician's perspectiveEGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsPreclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomographyAdjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.The Interactions between L-tyrosine based nanoparticles decorated with folic acid and cervical cancer cells under physiological flowCisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.The effect of tetrandrine combined with cisplatin on proliferation and apoptosis of A549/DDP cells and A549 cells.Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer.Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumorsPhase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancerClinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study.Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.Utility of day 8 blood tests on platinum plus vinorelbine regimen.Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.L-carnitine protects against carboplatin-mediated renal injury: AMPK- and PPARα-dependent inactivation of NFAT3.Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.MicroRNAs as lung cancer biomarkersExcision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapyMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: a single institute study.Lipoplatin formulation review article.A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancerLong noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients.
P2860
Q24200413-27B19994-6916-462A-A285-0FE170103728Q24235240-159CACFD-54FB-471B-807B-DA08E0C92623Q24656144-108F5A79-34FD-4EFD-963D-C971D6F85247Q26740988-57873648-49AC-4F19-82DE-DD095EC0EDD3Q26775817-473315AA-09DC-4239-839D-99A8611B5483Q26824528-EF143999-634C-41ED-8CD0-9ED4DAC19EC5Q26865662-F019B21A-4A2D-4B32-AE91-B128D661EB91Q26999304-67671CF7-FAC6-44E5-8324-F0CC254A9384Q27852543-39320962-D65A-4C97-BF1E-7C1B3C86866FQ28079705-E6C9CC52-B2BB-4EA7-A2BF-08BFFFE64EACQ28540769-471BEBAA-F57F-4A21-8F24-63472E07D621Q30438068-933F2C82-79BF-48A2-876A-39E8DE0344B6Q30529631-88D79AAF-DA82-4EF1-BB9F-F901003C3F5CQ30784508-134C8928-1E1A-4FD2-9E3E-9E658C5F48A8Q32179390-2F088CF1-AA73-41BF-BF45-6185796C8720Q33390996-FEB1AD20-2429-438C-A6F7-098F45BE19EDQ33391003-BF45390D-4CF3-437C-A2A8-67F7C179E38DQ33392779-BF4AAB65-13ED-4EAE-AD69-F1D4AB6649C0Q33396369-65B72DD3-4532-4646-8D19-991A63475E6EQ33397163-30A85698-1D20-4BA4-9C90-28D6552E0D98Q33398466-4918060D-E5C6-46CA-92FC-D03F5FD0687AQ33400988-78633D02-3274-4769-A5A9-A7930750325BQ33406952-7ED31735-E1ED-4CF4-BA81-19C462210DC6Q33407219-94C30973-B9E9-4FA8-B1EA-87390C8A5D42Q33414911-F161AB65-64A3-44EB-9B91-C78186B65129Q33419258-E6173858-2EBC-49DD-9871-ACFB5789854FQ33429178-8210B07E-D5A6-4D0E-90E1-86F7BC9D9E05Q33432128-E46462BB-C54A-4C80-9873-BAD104F59A43Q33523365-61BD18AE-54E2-4BE7-8C7A-1FB1BE3E239DQ33751771-0AD5D4C3-AC93-4AE6-942D-2F84AC31353BQ34000195-004A17A0-8348-4537-9529-5171BE61887FQ34005272-4BFF80BF-D6A8-48FD-88B2-0E0152ADFF5FQ34031213-21516150-CF03-4C53-82B0-211ACD98418BQ34055535-B69FB652-B7A8-49C9-86D2-058A3BF5F9A1Q34076429-E83BEE8C-320A-422C-B83A-C58ABFFA6A49Q34121219-865A393F-803F-407F-A192-0D80008C7373Q34146137-58B157C4-F78C-43F7-B51E-1CE753488E68Q34214923-C9F671B0-7EC4-4B3F-9D08-D5DD8BE0BF72Q34243429-D220E644-DFB5-4A1D-81A6-D4DC893D165CQ34252809-698F1710-5337-4C41-9918-2FBC36AF653E
P2860
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@ast
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@en
type
label
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@ast
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@en
prefLabel
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@ast
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@en
P2093
P2860
P50
P921
P356
P1476
Cisplatin- versus carboplatin- ...... al patient data meta-analysis.
@en
P2093
Adriano Paccagnella
Andrea Ardizzoni
CISCA (CISplatin versus CArboplatin) Meta-analysis Group
Davorin Radosavljevic
Donald Bisset
Joan H Schiller
Marianne Paesmans
Paola Mazzanti
Petr Zatloukal
P2860
P304
P356
10.1093/JNCI/DJK196
P407
P577
2007-06-01T00:00:00Z